Bulletin
Investor Alert

New York Markets Open in:

Alkermes PLC

NAS: ALKS

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 12, 2022, 5:21 p.m.

/zigman2/quotes/205084517/composite

$

27.07

Change

+0.92 +3.52%

Volume

Volume 18,709

Quotes are delayed by 20 min

/zigman2/quotes/205084517/composite

Previous close

$ 25.47

$ 26.15

Change

+0.68 +2.67%

Day low

Day high

$25.33

$26.16

Open

52 week low

52 week high

$21.24

$33.00

Open

Company Description

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVIT...

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Valuation

Price to Sales Ratio

3.19

Price to Book Ratio

3.39

Price to Cash Flow Ratio

31.59

Enterprise Value to EBITDA

82.31

Enterprise Value to Sales

3.46

Efficiency

Total Asset Turnover

0.59

Liquidity

Current Ratio

2.25

Quick Ratio

1.93

Cash Ratio

1.14

Profitability

Gross Margin

78.89

Operating Margin

-2.50

Pretax Margin

-3.35

Net Margin

-4.10

Return on Assets

-2.42

Return on Equity

-4.42

Return on Total Capital

-1.95

Capital Structure

Total Debt to Total Assets

20.56

Officers and Executives

Name Age Officer Since Title
Mr. Richard F. Pops 58 1991 Chief Executive Officer & Director
Mr. Blair C. Jackson 47 1999 Senior Vice President-Corporate Planning
Mr. Iain Michael Brown 50 2003 Chief Accounting Officer & Senior VP-Finance
Ms. Sondra Smyrnios - 2019 Senior Vice President-Clinical Operations
Dr. Kanchan Relwani - 2017 Senior Vice President-Medical Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/21/2022 C. Todd Nichols
SVP, Chief Commercial Officer
7,474   Disposition at $28.26 per share. 211,215
06/14/2022 Shane M. Cooke
Director
3,945   Derivative/Non-derivative trans. at $27.19 per share. 107,264
06/14/2022 David Antonio Daglio
Director
795   Derivative/Non-derivative trans. at $27.19 per share. 21,616
06/14/2022 Nancy J. Wysenski
Director
695   Derivative/Non-derivative trans. at $27.19 per share. 18,897
06/14/2022 Brian Patrick McKeon
Director
795   Derivative/Non-derivative trans. at $27.19 per share. 21,616
06/14/2022 Nancy L. Snyderman
Director
695   Derivative/Non-derivative trans. at $27.19 per share. 18,897
06/14/2022 Frank Anders Wilson
Director
695   Derivative/Non-derivative trans. at $27.19 per share. 18,897
06/14/2022 Richard B. Gaynor
Director
695   Derivative/Non-derivative trans. at $27.19 per share. 18,897
06/14/2022 Emily Peterson Alva
Director
905   Derivative/Non-derivative trans. at $27.19 per share. 24,606
06/14/2022 Shane M. Cooke
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 David Westbrook Anstice
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 David Antonio Daglio
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Wendy L. Dixon
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Nancy J. Wysenski
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Brian Patrick McKeon
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Nancy L. Snyderman
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Frank Anders Wilson
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Richard B. Gaynor
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Emily Peterson Alva
Director
7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/09/2022 Emily Peterson Alva
Director
304   Derivative/Non-derivative trans. at $28.13 per share. 8,551
06/09/2022 Emily Peterson Alva
Director
43   Derivative/Non-derivative trans. at $28.13 per share. 1,209
06/09/2022 Emily Peterson Alva
Director
3,796   Derivative/Non-derivative trans. at $0 per share. 0
06/09/2022 Emily Peterson Alva
Director
532   Derivative/Non-derivative trans. at $0 per share. 0
06/05/2022 C. Todd Nichols
SVP, Chief Commercial Officer
1,029   Derivative/Non-derivative trans. at $29.31 per share. 30,159
06/05/2022 C. Todd Nichols
SVP, Chief Commercial Officer
3,500   Derivative/Non-derivative trans. at $0 per share. 0
05/17/2022 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
50,000   Disposition at $29.15 per share. 1,457,500
05/17/2022 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
50,000   Derivative/Non-derivative trans. at $16.55 per share. 827,500
05/10/2022 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
25,000   Disposition at $27.22 per share. 680,500
05/10/2022 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
25,000   Derivative/Non-derivative trans. at $16.55 per share. 413,750
05/06/2022 Richard F. Pops
Director and CEO, Alkermes plc; Director
93,747   Disposition at $27.85 per share. 2,610,853
05/06/2022 Richard F. Pops
Director and CEO, Alkermes plc; Director
120,847   Derivative/Non-derivative trans. at $16.55 per share. 2,000,017
05/05/2022 Richard F. Pops
Director and CEO, Alkermes plc; Director
32,288   Disposition at $28.59 per share. 923,113
05/05/2022 Richard F. Pops
Director and CEO, Alkermes plc; Director
221,222   Disposition at $27.95 per share. 6,183,154
05/05/2022 Richard F. Pops
Director and CEO, Alkermes plc; Director
329,153   Derivative/Non-derivative trans. at $16.55 per share. 5,447,482
05/03/2022 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
25,000   Disposition at $28.62 per share. 715,500
05/03/2022 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
25,000   Derivative/Non-derivative trans. at $16.55 per share. 413,750
05/02/2022 Shane M. Cooke
Director
10,000   Disposition at $29.23 per share. 292,300
05/02/2022 Shane M. Cooke
Director
10,000   Derivative/Non-derivative trans. at $16.55 per share. 165,500
/news/latest/company/us/alks

MarketWatch News on ALKS

  1. How to Avoid the Biotech Bear Market: Get Some Products Approved

    9:33 p.m. May 13, 2022

    - Barron's Online

  2. Nektar Shares Halve on Cancer Trial Failure

    6:14 p.m. March 14, 2022

    - Barron's Online

  3. Alkermes downgraded to underperform from neutral at BofA Securities

    9:41 a.m. Sept. 2, 2021

    - Tomi Kilgore

  4. Alkermes stock halted for news pending

    7:00 a.m. June 1, 2021

    - Tomi Kilgore

  5. Biotech Is Down. How It Could Come Back.

    9:41 a.m. May 17, 2021

    - Barron's Online

  6. The Case for AbbVie as a Top Biopharma Stock in 2021

    9:45 a.m. Jan. 7, 2021

    - Barron's Online

  7. Alkermes upgraded to buy from neutral at Mizuho

    6:35 a.m. Oct. 15, 2020

    - Tomi Kilgore

  8. Alkermes stock price target raised to $24 from $19 at Mizuho

    6:04 a.m. Oct. 15, 2020

    - Tomi Kilgore

  9. Alkermes downgraded to neutral from buy at BofA Securities

    11:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  10. Alkermes stock price target cut to $20 from $31 at BofA Securities

    11:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  11. Alkermes downgraded to neutral from overweight at J.P. Morgan

    8:51 a.m. Feb. 14, 2020

    - Tomi Kilgore

  12. Alkermes stock price target cut to $21 from $25 at J.P. Morgan

    8:52 a.m. Feb. 14, 2020

    - Tomi Kilgore

  13. FDA told Alkermes to stop publishing Vivitrol ad

    1:12 p.m. Dec. 11, 2019

    - Jaimy Lee

  14. Alkermes to acquire Rodin Therapeutics for up to $950 million

    8:30 a.m. Nov. 18, 2019

    - Ciara Linnane

  15. Biogen shares fall 3%

    4:08 p.m. Nov. 14, 2019

    - Jaimy Lee

  16. Biogen, Alkermes MS treatment Vumerity gets FDA approval

    7:33 a.m. Oct. 30, 2019

    - Tomi Kilgore

  17. Loading more headlines...
/news/nonmarketwatch/company/us/alks

Other News on ALKS

  1. Here's Why You Should Buy Patterson Companies (PDCO) Stock

    10:33 a.m. Aug. 12, 2022

    - Zacks.com

  2. Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

    10:33 a.m. Aug. 12, 2022

    - Zacks.com

  3. 3 Companies Growing Revenue Fast

    1:23 p.m. Aug. 10, 2022

    - GuruFocus.com

  4. Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat

    12:14 p.m. Aug. 9, 2022

    - Zacks.com

  5. Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss

    12:42 p.m. Aug. 8, 2022

    - Zacks.com

  6. Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates

    10:53 a.m. Aug. 8, 2022

    - Zacks.com

  7. QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View

    12:57 p.m. Aug. 5, 2022

    - Zacks.com

  8. AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates

    12:56 p.m. Aug. 5, 2022

    - Zacks.com

  9. Loading more headlines...

At a Glance

Alkermes Plc

Connaught House

1 Burlington Road

Dublin, Dublin 4

Phone

353 17728000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$1.17B

Net Income

$-48.17M

Employees

2,211

/news/pressrelease/company/us/alks

Press Releases on ALKS

  1. Alkermes plc Reports Second Quarter 2022 Financial Results

    7:00 a.m. July 27, 2022

    - PR Newswire - PRF

  2. Alkermes to Report Second Quarter Financial Results on July 27, 2022

    4:00 p.m. July 20, 2022

    - PR Newswire - PRF

  3. Sarissa Capital Comments on Alkermes Annual Meeting

    7:04 a.m. July 6, 2022

    - BusinessWire - BZX

  4. Alkermes to Participate in the Goldman Sachs Healthcare Conference

    4:00 p.m. June 8, 2022

    - PR Newswire - PRF

  5. Alkermes to Participate in the Jefferies Healthcare Conference

    4:00 p.m. June 1, 2022

    - PR Newswire - PRF

  6. Sarissa Condemns Poor Corporate Governance at Alkermes

    9:43 a.m. May 27, 2022

    - BusinessWire - BZX

  7. Alkermes to Report First Quarter Financial Results on April 27, 2022

    4:00 p.m. April 20, 2022

    - PR Newswire - PRF

  8. Alkermes to Participate in the Stifel 2022 CNS Days

    4:00 p.m. March 22, 2022

    - PR Newswire - PRF

  9. Loading more headlines...
Link to MarketWatch's Slice.